Summit had a busy end to calendar year 2017 entering into an exclusive licence and commercialisation agreement with Eurofarma Laboratorios SA for Latin American rights to ridinilazole (group’s antibiotic in development for C. difficile infection) as well as acquiring Discuva for £10m in cash and shares. We detail both in this note and flag the important upcoming development milestones from both of the group’s clinical programmes. Interim 24-week data from the PhaseOut DMD trial is expected in Q1 ....
05 Jan 2018
Busy end to CY’17 - upcoming PhaseOut DMD data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Busy end to CY’17 - upcoming PhaseOut DMD data
Summit had a busy end to calendar year 2017 entering into an exclusive licence and commercialisation agreement with Eurofarma Laboratorios SA for Latin American rights to ridinilazole (group’s antibiotic in development for C. difficile infection) as well as acquiring Discuva for £10m in cash and shares. We detail both in this note and flag the important upcoming development milestones from both of the group’s clinical programmes. Interim 24-week data from the PhaseOut DMD trial is expected in Q1 ....